Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds JonesTrading Upgrades Deciphera Pharmaceuticals to Hold

JonesTrading Upgrades Deciphera Pharmaceuticals to Hold

JonesTrading analyst Soumit Roy upgrades Deciphera Pharmaceuticals (NASDAQ:DCPH) from Sell to Hold.

byBenzinga Newsdesk

January 6, 2023

1 minute read

JonesTrading analyst Soumit Roy upgrades Deciphera Pharmaceuticals (NASDAQ:DCPH) from Sell to Hold.

Alzheimer’s Progression Slowed Down By Biogen’s New Drug In Late-Stage Study: Analyst Sees 25% Upside For Stock

By Shanthi Rexaline

September 28, 12:35 AM

Biogen, Inc. (NASDAQ: BIIB) and Eisai Co. Ltd. (OTC: ESALY) announced late Tuesday positive results from a late-stage study of their Alzheimer’s treatment candidate.

BIIB

A Look Into Fortinet Inc’s Price Over Earnings

By Benzinga Insights

July 6, 12:21 PM

In the current market session, Fortinet Inc. (NASDAQ:FTNT) stock price is at $74.07, after a 0.32% drop. However,…

FTNT

Cowen & Co. Maintains Outperform on Enphase Energy, Raises Price Target to $341

By Benzinga Newsdesk

February 8, 11:03 AM

Cowen & Co. analyst Jeffrey Osborne maintains Enphase Energy (NASDAQ:ENPH) with a Outperform and raises the price target from $335 to $341.

ENPH

Truist Securities Maintains Buy on Antero Resources, Lowers Price Target to $41

By Benzinga Newsdesk

February 13, 8:19 AM

Truist Securities analyst Neal Dingmann maintains Antero Resources (NYSE:AR) with a Buy and lowers the price target from $48 to $41.

JonesTrading Upgrades Deciphera Pharmaceuticals to Hold

Related Posts

Alzheimer’s Progression Slowed Down By Biogen’s New Drug In Late-Stage Study: Analyst Sees 25% Upside For Stock

A Look Into Fortinet Inc’s Price Over Earnings

Cowen & Co. Maintains Outperform on Enphase Energy, Raises Price Target to $341

Truist Securities Maintains Buy on Antero Resources, Lowers Price Target to $41